Arthneeti
Sale is live|00:00:00

RSWM Ltd Q4 FY25 Earnings Analysis

Published 15 Jul 2026 | Textiles & Apparels | Market Cap: ₹734 Cr

Price

207

Market Cap

₹734 Cr

P/E Ratio

11.8

Earnings Summary

- Q3FY25 revenue increased by 22.3% YoY to ₹1,196 crore; 9MFY25 revenue up 23.7% to ₹3,569 crore. - Company aims to turn PAT positive soon, targeting profitability by the coming quarter, improving from a loss of ₹8 crore in Q3FY25 (Page 6).

📊 Revenue & Sales Performance

- Q3FY25 revenue increased by 22.3% YoY to ₹1,196 crore; 9MFY25 revenue up 23.7% to ₹3,569 crore. - EBITDA grew 2.6 times YoY in Q3FY25, reflecting better capacity utilization and cost control. - Management targets >90% capacity utilization, focusing on profitable product mix and operational efficiency. - Positive outlook from stable cotton prices, favorable forex, and government incentives (textile budget increased from ₹3,342 crore in FY25 to ₹5,272 crore in FY26). - Export demand is recovering; India expected to gain from shifts away from Bangladesh due to economic/political issues. - Emphasis on sustainability and higher value-added products like mélange yarn, with improved demand expected. - FY26 and FY27 guidance not explicit but positive trends in operational efficiencies, demand, and government support suggest growth in sales and volumes ahead.

📈 Profitability & Margins

- Company aims to turn PAT positive soon, targeting profitability by the coming quarter, improving from a loss of ₹8 crore in Q3FY25 (Page 6). - EBITDA showed strong growth, up 2.6 times YoY in Q3FY25, with expectations of continued improvement due to cost control and better capacity utilization (Pages 4-5). - Management focusing on full capacity utilization (>90%) and product mix optimization to drive profitability (Page 9). - Sustainability initiatives including biofuels and renewable energy expected to reduce operational costs gradually, benefiting future earnings (Pages 9-10). - Long-term ROCE improvement targeted by reducing debt and optimizing finance costs through innovative financing methods such as TReDS (Page 10-11). - Export demand recovery and favorable policy support expected to enhance revenue and operating profit growth (Pages 4-5). - No major CAPEX planned currently; focus is on normal maintenance CAPEX to sustain operations without large capital outlays (Page 7).

🏗️ Capital Expenditure Plans

- RSWM Limited is currently undertaking only normal/routine CAPEX focused on maintaining machine health to ensure efficiency and productivity. - There are no plans for major modernization or large capital expenditures at present, especially given the negative PAT status. - The company aims to leverage recent capital expansions and focus on optimizing returns on existing investments. - Long-term consolidation of manufacturing facilities is a possibility but not targeted in the short to medium term due to high capital expenditure involved. - The company invested around ₹35-36 crores in sustainability initiatives such as biofuel-based boilers and solar/green energy sources, aiming to reduce operational costs and meet customer sustainability compliance. - Ongoing cost optimization and production improvement initiatives align with their annual business plan approved by the board. - No current plans to raise funds for new CAPEX; focus is on profitability and maintaining stringent cash flows.

💰 Fundraising & Capital Structure

- RSWM Limited has no current plans to raise new funds through debt or equity. - The company is focused on channelizing and making existing businesses profitable. - Emphasis is on stringent cash flow management and maintaining working capital without raising additional funds. - Short to medium-term strategy does not include shutting down or consolidating manufacturing units that would require capital expenditure. - The company is targeting normal CAPEX mainly for machinery maintenance and efficiency, avoiding major modernization due to recent financial challenges. - Off-balance sheet financing options like TReDS, factoring, channel financing, and vendor financing are being utilized to reduce finance costs. - The focus is on reducing existing debt through repayment plans and cost control rather than seeking fresh capital infusion.

📋 Order Book & Pipeline

- RSWM is currently focusing on ensuring a capacity utilization of more than 90%, which ties into managing their order book effectively. - The company is actively working on improving production and profitability based on their annual business plan approved by the board. - Management is targeting to shift production towards more profitable product mixes based on orders received. - Discussion around export orders indicates a positive demand recovery, especially from the apparel sector shifting business towards Indian manufacturers due to challenges in Bangladesh. - While exact current quantitative order book figures were not disclosed, the improvement in capacity utilization and export demand suggests a healthy and improving order flow. - The company remains cautious but optimistic about demand and pricing improvements, particularly in premium products like mélange yarn, expecting better capacity utilization in Q4 FY25.

Key Metrics

Frequently Asked Questions

What were RSWM Ltd Q4 FY25 results?

- Q3FY25 revenue increased by 22.3% YoY to ₹1,196 crore; 9MFY25 revenue up 23.7% to ₹3,569 crore. - Company aims to turn PAT positive soon, targeting profitability by the coming quarter, improving from a loss of ₹8 crore in Q3FY25 (Page 6).

What is RSWM Ltd share price analysis?

RSWM Ltd currently shows a neutral. The stock trades at a P/E of 11.8 with a market cap of ₹734. Investors should review the full earnings analysis for detailed insights.

Is RSWM Ltd planning capital expenditure?

- RSWM Limited is currently undertaking only normal/routine CAPEX focused on maintaining machine health to ensure efficiency and productivity.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.